← Back to Search

Behavioral Intervention

Therapy for Neurodevelopmental Treatment

N/A
Waitlist Available
Research Sponsored by MultiCare Health System Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up significant change after an 8 week ndt-cpm treatment occurring from november 2, 2021 to completion on march 12, 2022
Awards & highlights

Study Summary

This trial will study whether children with Cerebral Palsy and other neuromuscular disorders improve with Neurodevelopmental Treatment intervention using the contemporary practice model.

Eligible Conditions
  • Neurodevelopmental Treatment
  • Cerebral Palsy
  • Neuromuscular Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~significant change after an 8 week ndt-cpm treatment occurring from november 2, 2021 to completion on march 12, 2022
This trial's timeline: 3 weeks for screening, Varies for treatment, and significant change after an 8 week ndt-cpm treatment occurring from november 2, 2021 to completion on march 12, 2022 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Significant increase in functional outcomes in COPM scores

Side effects data

From 2020 Phase 3 trial • 100 Patients • NCT03537014
72%
Headache
61%
Muscle Tightness
52%
Decreased Appetite
46%
Suicidal Ideation
43%
Insomnia
33%
Anxiety
30%
Fatigue
30%
Nausea
26%
Viral Upper Respiratory Tract Infection
22%
Hyperhidrosis
20%
Feeling Cold
20%
Dizziness
15%
Nightmare
15%
Asthenia
15%
Mydriasis
15%
Restlnessness
13%
Dizziness Postural
13%
Nystagmus
13%
Tremor
13%
Bruxism
13%
Abdominal Discomfort
11%
Feeling Jittery
11%
Dry Mouth
11%
Back Pain
11%
Depressed Mood
11%
Upper Respiratory Tract Infection
11%
Blood Pressure Increased
11%
Paraesthesia
11%
Abdominal Pain Upper
9%
Vomiting
9%
Feeling Hot
9%
Musculoskeletal Pain
9%
Palpitations
9%
Non-Cardiac Chest Pain
9%
Vision Blurred
9%
Depression
9%
Disturbance in Attention
9%
Stress
9%
Intrusive Thoughts
9%
Pain
9%
Pollakiuria
9%
Feeling of Body Temperature Change
9%
Arthralgia
9%
Temperature Intolerence
7%
Muscle Spasms
7%
Chills
7%
Muscle Twitching
7%
Flashback
7%
Pain in Jaw
7%
Anger
7%
Micturition Urgency
7%
Nervousness
7%
Feeling Abnormal
7%
Hypoaesthesia
7%
Somnolence
7%
Substance Use
7%
Ear Pain
7%
Myalgia
7%
Vertigo
7%
Influenza
7%
Dysmenorrhoea
7%
Pyrexia
4%
Influenza Like Illness
4%
Diarrhea
4%
Emotional Disorder
4%
Irritability
4%
Neck Pain
4%
Agitation
4%
Oropharyngeal Pain
4%
Emotional Distress
4%
Dissociation
4%
Panic Attack
2%
Intentional Self-Injury
100%
80%
60%
40%
20%
0%
Study treatment Arm
MDMA-assisted Therapy
Placebo With Therapy

Trial Design

1Treatment groups
Experimental Treatment
Group I: NDTExperimental Treatment1 Intervention
Therapy will be provided 2 days to 4 days per week for one-hour sessions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Therapy
2014
Completed Phase 3
~990

Find a Location

Who is running the clinical trial?

MultiCare Health System Research InstituteLead Sponsor
12 Previous Clinical Trials
1,012 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
NDT Effectiveness Study
2021. "NDT Effectiveness Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05070910.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top